Delivery of temozolomide and N3-propargyl analog to brain tumors using an apoferritin nanocage

Glioblastoma multiforme (GBM) is a grade IV astrocytoma, which is the most aggressive form of brain tumor. The standard of care for this disease includes surgery, radiotherapy and temozolomide (TMZ) chemotherapy. Poor accumulation of TMZ at the tumor site, tumor resistance to drug, and dose-limiting bone marrow toxicity eventually reduce the success of this treatment. Herein, we have encapsulated >500 drug molecules of TMZ into the biocompatible protein nanocage, apoferritin (AFt), using a "nanoreactor" method (AFt-TMZ). AFt is internalized by transferrin receptor 1-mediated endocytosis and is therefore able to facilitate cancer cell uptake and enhance drug efficacy. Following encapsulation, the protein cage retained its morphological integrity and surface charge; hence, its cellular recognition and uptake are not affected by the presence of this cargo. Additional benefits of AFt include maintenance of TMZ stability at pH 5.5 and drug release under acidic pH conditions, encountered in lysosomal compartments. MTT assays revealed that the encapsulated agents displayed significantly increased antitumor activity in U373V (vector control) and, remarkably, the isogenic U373M (MGMT expressing TMZ-resistant) GBM cell lines, with GI50 values 500 molecules of the N3-propargyl imidazotetrazine analog (N3P), developed to combat TMZ resistance, and demonstrated significantly enhanced activity of AFt-N3P against GBM and colorectal carcinoma cell lines. These studies support the use of AFt as a promising nanodelivery system for targeted delivery, lysosomal drug release, and enhanced imidazotetrazine potency for treatment of GBM and wider-spectrum malignancies

Modulation of the acidity of the 8-carboxamide group in the temozolomide family of antitumor imidazo[5,1-d][1,2,3,5]tetrazines

Imidazo[5,1-d][1,2,3,5]tetrazines related in structure to the anticancer drugs temozolomide and mitozolomide with modification of the 8-carboxamide group, have been synthesized, N-nitrocarboxamides by direct nitration of the corresponding carboxamides, and N-cyanomitazolomide by sodium cyanamide acylation. The NH groups in the N-nitro- and N-cyano-carboxamides were considerably more acidic than the parent carboxamide, and readily formed salts with morpholine and imidazole. X-Ray crystallography revealed that the N-nitro compound existed as such rather than the nitronic acid tautomer. Preliminary evaluation showed that enhancing the acidity of the carboxamide NH in mitozolomide analogues was detrimental to the growth inhibitory activity

Evaluating and Improving the Visualisation of CHOOSE, an Enterprise Architecture Approach for SMEs

International audienceEnterprise architecture (EA) serves as a means to improve business-IT and strategy-operations alignment in an organisation. While it is a fairly mature domain in large enterprises, the need for EA in small and medium-sized enterprises (SMEs) has only been recently addressed. As SMEs have different characteristics and cope with specific problems, a different approach is essential to enable a successful adoption of EA. In order to meet these particular requirements of SMEs, the EA approach CHOOSE has been developed. In previous research, emphasis has been put on refining the method and metamodel of CHOOSE and on the development of supporting software tools. However, the visual notation of CHOOSE has not been investigated yet, while the form of representation has a great impact on the cognitive effectiveness of a diagram. This paper assesses the current visualisation of CHOOSE, describes alternatives and conducts an experimental comparison